Coronary DiseaseCCT/MPERFNCT02361996
Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients
An observational study of Coronary Disease and Aortic Valve Stenosis, run by Bakulev Scientific Center of Cardiovascular Surgery at 3 sites in 3 countries.
Trial summary
It is a common understanding that patients with coronary heart disease are suffering, among others, from reduced myocardial perfusion. In order to increase (normalize) the reduced perfusion, when a conventional approach failed, coronary bypass surgery, coronary vessel dilatation or stenting are performed. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Disease, Aortic Valve Stenosis
- How many people
- 690 participants
- Where
- 3 sitesin 3 countries
- Study dates
- Feb 2015to Apr 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients above 18 years of age, who are reffered with suspected or known coronary artery disease or aortic valve stenosis either to the Bakoulev Scientific Centre for Cardiovascular Surgery, Moscow / Russia or to the Republican Special Centre of Surgery, Tashkent / Uzbekistan and fulfill the eligibility criteria.
Who may be able to join
- in cohort: Coronary Bypass Surgery:
- o presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery
- in cohort: Coronary Stenting: o presence of at least one coronary stenotic lesion above 50% with indication for coronary vessel dilatation/stenting
- in cohort: Aortic Valve Replacement
- o presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50%
- for all three cohorts:
- list of medication timely related to the procedure
- signed informed consent
Who cannot join
- for all three cohorts:
- intolerance to contrast agent
- multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection
- renal failure
- severe arrhythmia
- pregnancy
Show all 10Show fewer
- reduction of cognitive capabilities to understand the purpose and the extent of the study
- participation in a medical-scientific study using X-rays in the last ten years
- lack of Russian knowledge to fill the forms
- lack of signed study agreement -
Trial locations and contacts
3 sites in 3 countries.
3 sites in 3 countries
Russia1 site
Bakoulev Scientific Center for Cardiovascular Surgery
Moscow, 121552
About this study
Official title: Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients Before and After Coronary-bypass-surgery, Before and After Dilating/Stenting and Before and After Aortic-valve-replacement.
It is a common understanding that patients with coronary heart disease are suffering, among others, from reduced myocardial perfusion. In order to increase (normalize) the reduced perfusion, when a conventional approach failed, coronary bypass surgery, coronary vessel dilatation or stenting are performed. The similar situation with reduced myocardial perfusion may be found in patients with stenosis of the aortic valve, where aortic valve replacement may increase myocardial perfusion by left-ventricular remodelling. However, there is presently no method established to measure myocardial perfusion quantitatively and noninvasively before and after a therapeutic intervention.
Data of pre- and post-therapeutic myocardial perfusion, quantitatively measured in ml/100g/min would strengthen the indication for specific therapeutic approach and enable an objective control of effectiveness of the applied therapy.
Read more
Hypothesis:
There is a measureable difference in quantitative myocardial perfusion values before (lower) and after (higher) interventional or surgical procedure.
The goal of the study is to measure myocardial perfusion by advanced CT technology (e.g. iCT 256 Brilliance ) quantitatively in ml/100g/min in three groups of patients:
- Before and after coronary bypass surgery
- Before and after coronary vessel dilatation/stenting
- Before and after aortic valve replacement.
The investigators will not assign specific interventions to the subjects of these three groups. Therefore, the research is strictly observational.
Design:
Prospective study to measure quantitatively myocardial perfusion in the above mentioned three groups of patients with simultaneous control and registration of all essential, physiological determinants of myocardial perfusion immediately prior to each CT study. The CT myocardial perfusion measurements will be performed directly after the indication for intervention or surgery and on the last day before discharge from hospital.
All the collected data (determinants) inclusively the CT-studies will be anonymised and archived on a local server. The investigators of the University of Medical Computed Sciences and Technology, Innsbruck / Austria will perform the evaluation of the myocardial perfusion measurements and all statistical analysis independently of the CT-studies performing physicians.
Read the detailed description
Reliability of the hypothesis:
On phantom studies simulating myocardial perfusion measurements and in animal studies we could confirm that using advanced CT technology (as e.g. "iCT 256 Brilliance") it is possible to measure myocardial perfusion in absolute values - in ml/100g/min. These myocardial perfusion measurements did not differ from those received by EBCT (Electron Beam Computed Tomography). Based on these experimental results and based on the quantitative measurements of myocardial perfusion in 1500 patients studied by EBCT at the Medical University of Graz the hypothesis may be done that using the above mentioned iCT 256 technology, it should be possible to measure myocardial perfusion quantitatively in a daily clinical practice.
Ethical aspects:
The study will be performed according to the international regulations (ISO 14144:212-01) and in agreement with the "Declaration of Helsinki". After oral and written explanation of the planned study and by signing the study agreement by patient and by responsible physician, patients participation is voluntary. The patients participating can leave the study any time without negative sequels for him or her. There is no financial restitution for the patients.
Patients will be informed about (very rare) possible allergoid-toxic reactions during and after intravenous contrast agent application. For possible emergency well trained medical staff and equipment is present. About renal insufficiency: renal failure (creatinin clearance <60ml/min [GFR (Glomerulo Filtration Rate)will be calculated according the Cockroft-Gault-Formula, GFR {ml/min}=((40-age)*weight{kg}*0,85{only for women}]/serum creatinin [mg/dl]*72) above.
The applied X-ray dose (CT) may and will be reduced by:
reduction of KV (kilovoltage) from 120 to 100 or 80 in dependance of patients weight, reduction of MA (milliamper)by using iterative image reconstruction allgorithm (iDOSE). These technical approaches represent the best possibility to reduce X-ray dose for the patient. As the coronary heart disease with stenotic lesions above 50% is a disease mainly of an elderly men (in female mostly after menopause and in male after 50 years of age) the risk for X-Ray dose related genetic defects is very low. The expected applied X-Ray doses by the above mentioned approach will be very low and therefore the risk of X-Ray induced malignancy may be regarded as very low too.
Design:
Prospective study to measure quantitatively myocardial perfusion in the above mentioned three groups of patients with simultaneous control and registration of all essential, physiological determinants of myocardial perfusion immediately before the CT study. The CT myocardial perfusion measurements will be performed directly after the indication for intervention or surgery and on the last day before discharge from hospital.
All the collected data (determinants) including the CT-studies will be anonymised and archived on a local server. These anonymised data may be approached only by members of Graz University of Technology, Institute of Health Care Engineering who will perform the evaluation of the myocardial perfusion measurements and the statistical analysis independently of the CT-studies performing physicians.
Practical procedure:
- In supine position on CT table the blood pressure and the heart rate will be measured and registered.
- In all patients a standard native cardiac CT for evaluation of coronary calcification by Agatston score will be performed.
- In all patients myocardial perfusion will be measured in inspiration and contrast agent application where by the amount of contrast agent and the applied dose is related to patient weights as shown below: Patient Perfusion 210mg Iodine/ml Expected dose weight [kg] / [kV/mAs] / [ml] / per shoot [mSv](milli Sievert) <60 80/80 40 0.21/ 60-70 80/100 50 0.25/ 70-90 80/120 60 0.30/ 90-100 100/90 70 0.40/ >100 100/100 80 0.43
- Standard cardiac CT will be performed to evaluate coronary arteries and left ventricular volumes.
- In supine position on CT table the blood pressure and the heart rate will be measured and registered.
Quantitative evaluation:
The calculation of the myocardial perfusion succeeds in all slices with visible left ventricular myocardium using a modification of the formula described by K.Miles and model based approaches.
The calculation of the left ventricular volumes succeeds by use of the vendors software.
Statistic:
All personal and measured data will be anonymised, tested, analysed and evaluated in Graz University of Technology.
The numerical values will be expressed as mean +/- SD (min, max, 95% CI). p-values of 0.05 will be regarded statistically significant. Paired test and or Wilcoxon signed-rank tests will be used. X² analyses will be used to compare categoric variables. Additionally correlation analyses (Pearson, Spearman) will be performed and method of classification (pre- vs. postoperative) will be applied. All calculation will be done by SPSS 21.0 (SPSS, Chicago, Il, USA) or by Matlab statistic toolbox or R.
The neccessary number of studied patients is based on the results of 64 patients studied before and after aortic valve replacement in whom the myocardial perfusion was measured before and four months after surgery.
Pre-operative: Mean=74 (SD=21) ml/100g/min Post 4 Months: Mean=78 (SD=20) ml/100g/min. Difference= +4ml/100g/min. With 0.5 supposed correlation of the measured values the standard deviation of the differences may be estimated as 20ml/100g/min.
By alpha=0.05, 1-beta=0.80, n=209 patients is needed.
In addition to the pre- and post surgery evaluation, statistical models explaining the influence of collected data on the quantitaitve myocardial perfusion will be computed.
As a drop-out quote of 10% may be expected it is neccessary to study in each group of patients 230 patients. This means total 690 patients.
All data will be registered in database and tested for plausibility.
- Conditions
- Coronary Disease, Aortic Valve Stenosis
- Medical subject headings
- Coronary Disease, Aortic Valve Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Coronary Bypass Surgery | inclusion criteria: * presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery. * list of medication timely related to the procedure * signed informed consent exclusion criteria: * intolerance to contrast agent * multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection * renal failure * severe arrhythmia * pregnancy * reduction of cognitive capabilities to understand the purpose and the extent of the study * participation in a medical-scientific study using X-rays in the last ten years * lack of Russian knowledge to fill the forms * lack of signed study agreement | |
| Coronary Stenting | inclusion criteria: * presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary vessel dilatation/stenting. * list of medication timely related to the procedure * signed informed consent exclusion criteria: * intolerance to contrast agent * multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection * renal failure * severe arrhythmia * pregnancy * reduction of cognitive capabilities to understand the purpose and the extant of the study * participation in a medical-scientific study using X-rays in the last ten years * lack of Russian knowledge to fill the forms * lack of signed study agreement | |
| Aortic Valve Replacement | inclusion criteria: * presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50% * list of medication timely related to the procedure * signed informed consent exclusion criteria: * intolerance to contrast agent * multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection * renal failure * severe arrhythmia * pregnancy * reduction of cognitive capabilities to understand the purpose and the extent of the study * participation in a medical-scientific study using X-rays in the last ten years * lack of Russian knowledge to fill the forms * lack of signed study agreement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of myocardial perfusion (ml/100g/min) [MPerf]
after indication for and before intervention or surgery and after intervention or surgery one day before discharge
Measured: 2015 - 2019
Secondary outcomes (1)
Composition of parameters influencing the complexity of myocardial perfusion regulation: Heart-rate, blood-pressure, rate-pressure-product, left ventricular haemodynamic parameters
after indication for and before intervention or surgery and after intervention or surgery one day before discharge
Measured: 2015 - 2019
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2015 (estimated)
- Study startFeb 2015
- Primary completionFeb 2022 (estimated)
- Study completionApr 2022 (estimated)
Why it stopped: Covid-19 Pandemic
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Coronary DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 690 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bakulev Scientific Center of Cardiovascular Surgery
- Sponsor type
- Other government
- Collaborators
- Medical University of Graz, Graz University of Technology
- Responsible party
- Principal investigator, Rainer Rienmueller, M.D., Bakulev Scientific Center of Cardiovascular Surgery
- Investigators
- Rainer K Rienmueller, MD, Study director, Bakoulev Scientific Centre for Cardiovascular Surgery; Medical University GrazVladimir N Makarenko, MD, Principal investigator, Bakoulev Scientific Centre for Cardiovascular Surgery, Moscow / RussiaMarat Khodjibekov, MD, Principal investigator, Republican Special Center of Surgery, Tashkent / UzbekistanTheresa Rienmüller, Dr.techn., Principal investigator, Graz University of Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02361996
- Sponsor's protocol ID
- RENE271242
- Acronym
- CCT/MPERF
- Status last verified
- Jul 2021
- First submitted
- 15 Jan 2015
- Last updated
- 16 Jul 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Rienmuller T, Baumgartner C, Handler M, Makarenko V, Ourednicek P, Krestinich IM, Zhorzholiani ST, Rienmuller R, Bockeria L. Quantitative Estimation of Left Ventricular Myocardial Perfusion Based on Dynamic CT Scans. Biomed Tech (Berl). 2013 Aug;58 Suppl 1:/j/bmte.2013.58.issue-s1-L/bmt-2013-4288/bmt-2013-4288.xml. doi: 10.1515/bmt-2013-4288. Epub 2013 Sep 7. No abstract available.
PubMed 24042936Lara-Hernandez A, Rienmuller T, Juarez I, Perez M, Reyna F, Baumgartner D, Makarenko VN, Bockeria OL, Maksudov M, Rienmuller R, Baumgartner C. Deep Learning-Based Image Registration in Dynamic Myocardial Perfusion CT Imaging. IEEE Trans Med Imaging. 2023 Mar;42(3):684-696. doi: 10.1109/TMI.2022.3214380. Epub 2023 Mar 2.
PubMed 36227828
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients Before and After Coronary-bypass-surgery, Before and After Dilating/Stenting and Before and After Aortic-valve-replacement.
- ClinicalTrials.gov ID
- NCT02361996
- Acronym / sponsor ID
- CCT/MPERF / RENE271242
- Conditions
- Coronary Disease, Aortic Valve Stenosis
- Study type
- Observational
- Recruitment status
- SuspendedReason stopped: Covid-19 Pandemic
- Enrolment
- 690 participants (estimated)
- Lead sponsor
- Bakulev Scientific Center of Cardiovascular SurgeryOther government
- Collaborators
- Medical University of Graz, Graz University of Technology
- Study start
- Feb 2015 (actual)
- Primary completion
- Feb 2022 (estimated)
- Study completion
- Apr 2022 (estimated)
- First posted
- 12 Feb 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is a common understanding that patients with coronary heart disease are suffering, among others, from reduced myocardial perfusion. In order to increase (normalize) the reduced perfusion, when a conventional approach failed, coronary bypass surgery, coronary vessel dilatation or stenting are performed. The similar situation with reduced myocardial perfusion may be found in patients with stenosis of the aortic valve, where aortic valve replacement may increase myocardial perfusion by left-ventricular remodelling. However, there is presently no method established to measure myocardial perfusion quantitatively and noninvasively before and after a therapeutic intervention.
Data of pre- and post-therapeutic myocardial perfusion, quantitatively measured in ml/100g/min would strengthen the indication for specific therapeutic approach and enable an objective control of effectiveness of the applied therapy.
Hypothesis:
There is a measureable difference in quantitative myocardial perfusion values before (lower) and after (higher) interventional or surgical procedure.
The goal of the study is to measure myocardial perfusion by advanced CT technology (e.g. iCT 256 Brilliance ) quantitatively in ml/100g/min in three groups of patients:
- Before and after coronary bypass surgery
- Before and after coronary vessel dilatation/stenting
- Before and after aortic valve replacement.
The investigators will not assign specific interventions to the subjects of these three groups. Therefore, the research is strictly observational.
Design:
Prospective study to measure quantitatively myocardial perfusion in the above mentioned three groups of patients with simultaneous control and registration of all essential, physiological determinants of myocardial perfusion immediately prior to each CT study. The CT myocardial perfusion measurements will be performed directly after the indication for intervention or surgery and on the last day before discharge from hospital.
All the collected data (determinants) inclusively the CT-studies will be anonymised and archived on a local server. The investigators of the University of Medical Computed Sciences and Technology, Innsbruck / Austria will perform the evaluation of the myocardial perfusion measurements and all statistical analysis independently of the CT-studies performing physicians.
Detailed description
Reliability of the hypothesis:
On phantom studies simulating myocardial perfusion measurements and in animal studies we could confirm that using advanced CT technology (as e.g. "iCT 256 Brilliance") it is possible to measure myocardial perfusion in absolute values - in ml/100g/min. These myocardial perfusion measurements did not differ from those received by EBCT (Electron Beam Computed Tomography). Based on these experimental results and based on the quantitative measurements of myocardial perfusion in 1500 patients studied by EBCT at the Medical University of Graz the hypothesis may be done that using the above mentioned iCT 256 technology, it should be possible to measure myocardial perfusion quantitatively in a daily clinical practice.
Ethical aspects:
The study will be performed according to the international regulations (ISO 14144:212-01) and in agreement with the "Declaration of Helsinki". After oral and written explanation of the planned study and by signing the study agreement by patient and by responsible physician, patients participation is voluntary. The patients participating can leave the study any time without negative sequels for him or her. There is no financial restitution for the patients.
Patients will be informed about (very rare) possible allergoid-toxic reactions during and after intravenous contrast agent application. For possible emergency well trained medical staff and equipment is present. About renal insufficiency: renal failure (creatinin clearance <60ml/min [GFR (Glomerulo Filtration Rate)will be calculated according the Cockroft-Gault-Formula, GFR {ml/min}=((40-age)*weight{kg}*0,85{only for women}]/serum creatinin [mg/dl]*72) above.
The applied X-ray dose (CT) may and will be reduced by:
reduction of KV (kilovoltage) from 120 to 100 or 80 in dependance of patients weight, reduction of MA (milliamper)by using iterative image reconstruction allgorithm (iDOSE). These technical approaches represent the best possibility to reduce X-ray dose for the patient. As the coronary heart disease with stenotic lesions above 50% is a disease mainly of an elderly men (in female mostly after menopause and in male after 50 years of age) the risk for X-Ray dose related genetic defects is very low. The expected applied X-Ray doses by the above mentioned approach will be very low and therefore the risk of X-Ray induced malignancy may be regarded as very low too.
Design:
Prospective study to measure quantitatively myocardial perfusion in the above mentioned three groups of patients with simultaneous control and registration of all essential, physiological determinants of myocardial perfusion immediately before the CT study. The CT myocardial perfusion measurements will be performed directly after the indication for intervention or surgery and on the last day before discharge from hospital.
All the collected data (determinants) including the CT-studies will be anonymised and archived on a local server. These anonymised data may be approached only by members of Graz University of Technology, Institute of Health Care Engineering who will perform the evaluation of the myocardial perfusion measurements and the statistical analysis independently of the CT-studies performing physicians.
Practical procedure:
- In supine position on CT table the blood pressure and the heart rate will be measured and registered.
- In all patients a standard native cardiac CT for evaluation of coronary calcification by Agatston score will be performed.
- In all patients myocardial perfusion will be measured in inspiration and contrast agent application where by the amount of contrast agent and the applied dose is related to patient weights as shown below: Patient Perfusion 210mg Iodine/ml Expected dose weight [kg] / [kV/mAs] / [ml] / per shoot [mSv](milli Sievert) <60 80/80 40 0.21/ 60-70 80/100 50 0.25/ 70-90 80/120 60 0.30/ 90-100 100/90 70 0.40/ >100 100/100 80 0.43
- Standard cardiac CT will be performed to evaluate coronary arteries and left ventricular volumes.
- In supine position on CT table the blood pressure and the heart rate will be measured and registered.
Quantitative evaluation:
The calculation of the myocardial perfusion succeeds in all slices with visible left ventricular myocardium using a modification of the formula described by K.Miles and model based approaches.
The calculation of the left ventricular volumes succeeds by use of the vendors software.
Statistic:
All personal and measured data will be anonymised, tested, analysed and evaluated in Graz University of Technology.
The numerical values will be expressed as mean +/- SD (min, max, 95% CI). p-values of 0.05 will be regarded statistically significant. Paired test and or Wilcoxon signed-rank tests will be used. X² analyses will be used to compare categoric variables. Additionally correlation analyses (Pearson, Spearman) will be performed and method of classification (pre- vs. postoperative) will be applied. All calculation will be done by SPSS 21.0 (SPSS, Chicago, Il, USA) or by Matlab statistic toolbox or R.
The neccessary number of studied patients is based on the results of 64 patients studied before and after aortic valve replacement in whom the myocardial perfusion was measured before and four months after surgery.
Pre-operative: Mean=74 (SD=21) ml/100g/min Post 4 Months: Mean=78 (SD=20) ml/100g/min. Difference= +4ml/100g/min. With 0.5 supposed correlation of the measured values the standard deviation of the differences may be estimated as 20ml/100g/min.
By alpha=0.05, 1-beta=0.80, n=209 patients is needed.
In addition to the pre- and post surgery evaluation, statistical models explaining the influence of collected data on the quantitaitve myocardial perfusion will be computed.
As a drop-out quote of 10% may be expected it is neccessary to study in each group of patients 230 patients. This means total 690 patients.
All data will be registered in database and tested for plausibility.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Coronary Bypass Surgery | – | –inclusion criteria: * presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery. * list of medication timely related to the procedure * signed informed consent exclusion criteria: * intolerance to contrast agent * multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection * renal failure * severe arrhythmia * pregnancy * reduction of cognitive capabilities to understand the purpose and the extent of the study * participation in a medical-scientific study using X-rays in the last ten years * lack of Russian knowledge to fill the forms * lack of signed study agreement |
| Coronary Stenting | – | –inclusion criteria: * presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary vessel dilatation/stenting. * list of medication timely related to the procedure * signed informed consent exclusion criteria: * intolerance to contrast agent * multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection * renal failure * severe arrhythmia * pregnancy * reduction of cognitive capabilities to understand the purpose and the extant of the study * participation in a medical-scientific study using X-rays in the last ten years * lack of Russian knowledge to fill the forms * lack of signed study agreement |
| Aortic Valve Replacement | – | –inclusion criteria: * presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50% * list of medication timely related to the procedure * signed informed consent exclusion criteria: * intolerance to contrast agent * multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection * renal failure * severe arrhythmia * pregnancy * reduction of cognitive capabilities to understand the purpose and the extent of the study * participation in a medical-scientific study using X-rays in the last ten years * lack of Russian knowledge to fill the forms * lack of signed study agreement |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients above 18 years of age, who are reffered with suspected or known coronary artery disease or aortic valve stenosis either to the Bakoulev Scientific Centre for Cardiovascular Surgery, Moscow / Russia or to the Republican Special Centre of Surgery, Tashkent / Uzbekistan and fulfill the eligibility criteria.
Key inclusion criteria (8 listed)
- o presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery
- in cohort: Coronary Stenting: o presence of at least one coronary stenotic lesion above 50% with indication for coronary vessel dilatation/stenting
- in cohort: Aortic Valve Replacement
- o presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50%
- list of medication timely related to the procedure
Key exclusion criteria (10 listed)
- intolerance to contrast agent
- multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection
- renal failure
- severe arrhythmia
- pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change of myocardial perfusion (ml/100g/min) [MPerf]
Time frame: 2015 - 2019
after indication for and before intervention or surgery and after intervention or surgery one day before discharge
1 secondary outcome
Composition of parameters influencing the complexity of myocardial perfusion regulation: Heart-rate, blood-pressure, rate-pressure-product, left ventricular haemodynamic parameters
Time frame: 2015 - 2019
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2021.
- Background: PubMed 24042936Rienmuller T, Baumgartner C, Handler M, Makarenko V, Ourednicek P, Krestinich IM, Zhorzholiani ST, Rienmuller R, Bockeria L. Quantitative Estimation of Left Ventricular Myocardial Perfusion Based on Dynamic CT Scans. Biomed Tech (Berl). 2013 Aug;58 Suppl 1:/j/bmte.2013.58.issue-s1-L/bmt-2013-4288/bmt-2013-4288.xml. doi: 10.1515/bmt-2013-4288. Epub 2013 Sep 7. No abstract available.
- Derived from this study: PubMed 36227828Lara-Hernandez A, Rienmuller T, Juarez I, Perez M, Reyna F, Baumgartner D, Makarenko VN, Bockeria OL, Maksudov M, Rienmuller R, Baumgartner C. Deep Learning-Based Image Registration in Dynamic Myocardial Perfusion CT Imaging. IEEE Trans Med Imaging. 2023 Mar;42(3):684-696. doi: 10.1109/TMI.2022.3214380. Epub 2023 Mar 2.
- Bakoulev Scientific Center's SiteLink provided by the sponsor.
- Site of Graz University of TechnologyLink provided by the sponsor.
- Individual participant dataSharing planned: Yes
Related trials for Coronary Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rainer K Rienmueller, MD study director
Bakoulev Scientific Centre for Cardiovascular Surgery; Medical University Graz
Vladimir N Makarenko, MD principal investigator
Bakoulev Scientific Centre for Cardiovascular Surgery, Moscow / Russia
Marat Khodjibekov, MD principal investigator
Republican Special Center of Surgery, Tashkent / Uzbekistan
3 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Disease and Aortic Valve Stenosis, run by Bakulev Scientific Center of Cardiovascular Surgery at 3 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 16 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Austria, Russia, Uzbekistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of myocardial perfusion (ml/100g/min) [MPerf] (time frame: 2015 - 2019). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02361996, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2021.